Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300677 · ClinicalTrials.gov registry record · Phase 4
To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days
A Phase 4 study of Infections, Fungal, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00300677 is a Phase 4 study of Infections, Fungal that has completed, run by Pfizer. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00300677, a Phase 4 study of Infections, Fungal, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the amount of voriconazole in the brain after 2 loading doses and 3 maintenance doses over 3 days and compare it to the amount of voriconazole in the plasma.
Conditions Studied
Interventions
- DRUG voriconazole
Study Locations (1)
Massachusetts
- Pfizer Investigational Site - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300677
The ClinicalTrials.gov registry entry for NCT00300677 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infections, Fungal appearing as the primary indexed condition, and to 1 intervention - of which voriconazole is the first listed.
NCT00300677 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00300677 about?
NCT00300677 is a clinical study titled "To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days". To determine the amount of voriconazole in the brain after 2 loading doses and 3 maintenance doses over 3 days and compare it to the amount of voriconazole in the plasma.
What is the current status of trial NCT00300677?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2007-03. Estimated completion is 2008-08.
What conditions does trial NCT00300677 study?
This clinical trial studies the following conditions: Infections, Fungal.
What interventions are being tested in trial NCT00300677?
The interventions under investigation include: voriconazole (DRUG).
Who is sponsoring clinical trial NCT00300677?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infections, Fungal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.